Ecolab (ECL)
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
$279.28+0.11%
Close 2026-09-04 · 1-day change
NYSEMaterialsChemicals - SpecialtySnapshot 2026-09-04
Research Workspace
Put ECL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Achieve adjusted diluted EPS of about $8.53 in 2026: FY26 EPS guidance 8.05-8.25 vs target 8.43.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, guidance credibility.
View ManagementExpectations look high — the market is pricing in about 26% growth a year, above the roughly 11% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEcolab's growth in Life Sciences and strong organic sales growth support its valuation. Revenue grew 10% year over year, with a recent earnings call highlighting double-digit quarterly EPS growth. ECL trades at 35× P/E versus a peer median of 17×, indicating the market prices in more growth than forecast. The primary risk is a potential cut to EPS guidance, which could damage credibility. Peer multiples imply a price about 26% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-04. ECL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 24 analysts currently covering ECL (as of Sep 2026).
Based on 8 Wall Street analysts offering 12-month price targets for ECL in the last 4 months.
Continue this research
Compare ECL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ECL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put ECL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive strong organic sales growth and EPS expansion
Strong growth in Life Sciences supports organic sales growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $279.28
The last 12 months of price, then the range of analyst 12-month targets from today’s $279.28.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Maintain EPS growth
Raises EPS outlook, aligns with growth objectives.
Advances: Achieve quarterly EPS targets
Earnings call details align with achieving EPS targets.
Advances: Maintain EPS growth
Organic growth acceleration supports EPS growth objective.
Advances: Maintain EPS growth
Higher profit forecast supports EPS growth objective.
Threatens: Maintain EPS growth
EPS estimates cut could hinder growth objectives.
Advances: Maintain EPS growth
Upgrade suggests strong EPS growth potential from AI.
Acquisition enhances Ecolab's technological capabilities and growth potential.